Dose Optimization Design for Randomized Phase II Trials With Toxicity and Efficacy Endpoints
Several study designs for identifying optimal biological dose (OBD) have been proposed for phase I, II, and I/II clinical trials, considering toxicity and efficacy of anticancer drugs, especially molecular‐targeted therapies and immune checkpoint inhibitors. Among these, the multiple‐dose randomized phase II trial (MER...